Research progress of dupilumab in the treatment of refractory asthma
Bronchial asthma is a heterogeneous airway disease mediated by a variety of inflammatory cells,which is characterized by airway inflammation,airway hyperresponsiveness,and reversible airway obstruction. It usually manifests as wheezing,cough,shortness of breath,and dyspnea,affecting more than 350 million people worldwide. Currently,the treatment of asthma is mainly based on β2 receptor agonists,glucocorticoids,leukotriene receptor antagonists and other drugs. However,some patients with refractory asthma have poor control effect,obvious impairment of lung function,which seriously affect the quality of life of patients. As a kind of double inhibition of interleukin (IL)-4/IL-13 antibodies,dupilumab can reduce the acute onset of asthma and oral dosage of glucocorticoid,improve lung function,improve the quality of life of patients with few adverse reactions and good safety. This article reviews the recent research progress of dupilumab in the treatment of asthma,providing theoretical basis for better clinical treatment of refractory asthma.
万方数据
维普
